To the best of our knowledge, there are currently no ongoing clinical trials evaluating either anti-TNF-α agents, anti-IL-17 agents, IL-22 therapy, or other cytokine-targeted pharmacotherapies directly in patients with NAFLD or MASLD, despite some promising results from preclinical and observational human studies. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.